Rationale: PARP-inhibitors have a strong theoretical role in the effective treatment of BRCA-mutated cancers, with mixed clinical successes thus far in breast and ovarian cancers. The POLO trial assesses the PARP-inhibitor olaparib as maintenance therapy after standard first-line chemo for metastaticBRCA-mutated pancreatic cancer.
Betting Line: AstraZeneca let the cat out of the bag on this one before their first quarterly earnings report this year, so barring any post-hoc reviews you should go all-in on olaparib significantly prolonging the primary endpoint of progression-free survival. | Kindler, ASCO Plenary 2019


Popular Posts